-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1782 Myelodysplastic Syndromes in Latin-America - Results from a Novel International Registry: Re-Glam

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
adult, Study Population, Human
Saturday, December 10, 2022, 5:30 PM-7:30 PM

Sofia Grille, MD, PhD1, Elvira DRP Velloso, MD, PhD2*, Matilde Boada, MD. MSc3*, Elia Apodaca Chavez4*, Andres Gomez-De Leon, MD5, Anna Cecilia Rodríguez-Zuñiga, MD6*, Emmanuel Martínez Moreno, MD7*, Fernando Perez-Jacobo, MD8*, Graciela Alfonso, MD9*, Juan Carlos Serrano, MD10*, Natalia Tejeira, MD11*, Lilián Díaz, MD12*, Valentina Olivares, MD12*, Laura Kornblihtt, PhD13*, Sergio Schusterschitz, MD14* and Marcelo Iastrebner, MD15*

1Catedra de Hematologia, Hospital de Clínicas. Facultad de Medicina. Universidad de la Republica, Montevido, Uruguay
2Department of Hematology, Federal University of Ceará, Fortaleza, Brazil
3Cátedra de Hematología, Hospital de Clinicas Dr Manuel Quintela, Montevideo, Uruguay
4Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
5Servicio de Hematología, Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. José Eleuterio Gonzalez", Monterrey, Mexico
6Hematology, Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario Dr José Eleuterio González, Monterrey, Mexico
7Hospital General de México Dr. Eduardo Liceaga., Ciudad de México., Mexico
8Hematology and blood bank services, Hospital Central Norte PEMEX, CDMX, Mexico
9Hospital Nacional Prof. Alejandro Posadas., Buenos Aires, Argentina
10Unidad Hematológica Especializada, Cucuta, Colombia
11Cooperativa Médica de Flores. COMEFLO., Florida, Uruguay
12Servicio Medico Integral. SMI, Montevideo, Uruguay
13Hospital de Clínicas José de San Martín, Buenos Aires, Argentina
14HC-UFMG, Belo Horizonte, Minas Gerais, Brazil
15Sanatorio Sagrado Corazón, Ciudad Autónoma de Buenos Aires, Argentina

Background: It is very well known that information provided by clinical records and organized system platforms (registries) offer a holistic view of MDS patients’ characteristics and therapeutic aspects in real-life. The primary objective of this study was to analyze data from a novel MDS Latin-American Registry.

Methods: The registry started in April 2022. From April to July, patients with MDS or CMML diagnosed since January 2014 were reported from Argentina, Brazil, Colombia, Mexico, and Uruguay. The Research Electronic Data Capture (REDCap) platform was used, consisting of 298 fields to describe patient demographics; their biological characteristics; clinical manifestations; comorbidities; laboratory features; bone marrow studies; risk classification; treatments, and outcomes. According to the Ethics Committee, all subjects had to sign an inform consent. Descriptive statistics were used to summarize demographic, and clinical data, as well as treatment characteristics - overall and by risk groups.

Results: A total of 231 patients were included in this analysis. The mean age was 62.8 ± 16.9 years and the male to female ratio was 1.1:1. Baseline characteristics are described in Table 1. According to WHO’s 2016 classification, the following categories were reported: MDS-SLD 4.4%; MDS-RS 1.3%; MDS-MLD 34.5%; MDS-RS-MLD 4.4%; MDS-EB 24.9%; MDS with isolated del(5q) 2.2%; unclassifiable MDS 0.4%; therapy-related MDS 7.0%; CMML 10.9%; MDS-U 1.3%; MDS/MPN-RS-T 0.4%; aCML 0.4%; other 7.9%. The IPSS-R was: 3.4% Very Low; 62.3% Low; 17.9% Intermediate; 10.1% high-risk; and 6.3% very high-risk. The majority of patients had de novo MDS (95.2%), and 8.6% had hypoplastic MDS. The mean BM blast count was 3.5±4.3%. Iron staining was performed in 28.1%. BM biopsies were performed at the moment of diagnosis in 77.5% of cases, reported as hypercellular in 90.0% of them and with fibrosis (> grade 1) in 32%. Immunohistochemistry was performed in 53.7% and flow cytometry in 47.8% of patients. Cytogenetics was performed in 93.9% and FISH in 26.9%. Abnormal karyotype was detected in 38.2%. An NGS panel was performed in 35 (15.2%) patients.

Low-risk MDS accounts for the majority of patients in our registry (58%). Erythropoietin was given in 73 (69.5%) and growth factor therapy in 13 (11%) patients. Red blood cell transfusion was given to 59 (50%) patients. 31 (26%) of them received second-line treatment: 29 with HMA, and 2 with lenalidomide. 5 (4.2%) underwent allogenic transplant. 16 (13.7%) progressed to AML. The median overall survival was 4.19 (2.7-6.40) years.

High-risk MDS was reported in 42% of patients. Regarding treatment, 69 (80.2%) received HMA (AZA=65 and DEC=4), 4 (4.6%) chemotherapy, and 8 (9.3%) of them were administered a venetoclax-based therapy. Fifteen (17.4%) were transplanted and 46 (53.4%) progressed to AML. The median overall survival was 1.5 (1.2-2.0) years.

Conclusions: This novel and international registry showed preliminary MDS data from Latin-America. Our results revealed younger age at diagnosis, high number of patients undergoing allogenic transplant and OS according to literature. The expansion of this registry certainly improves our clinical practice.

Disclosures: Gomez-De Leon: AbbVie: Honoraria, Other: advisory board. Iastrebner: Abbvie: Honoraria, Other: Advisory Board, Speakers Bureau; BMS: Honoraria, Other: Advisory Board, Speakers Bureau.

*signifies non-member of ASH